The first prescriptions of medical cannabis flower are set to be available for patients on the French medical cannabis pilot programme, in the coming weeks.
The first batches of dried medical cannabis flower, provided by Aurora and distributed by Ethypharm, are now available to the healthcare professionals on the first-ever French pilot programme.
The two firms were selected by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers, following the launch of the trial earlier this year.
Up to 3,000 patients will benefit from the two-year trial led by ANSM.
The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) – developed by the Aurora Nordic, production facility in Odense, Denmark – were delivered a few weeks ago to the French authorities.
Aurora Nordic, the company’s largest greenhouse production facility on European soil. Credit: Aurora Cannabis
Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products.
They were nominated as the primary supplier for all the three lots they applied for, which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers).
Dried flowers are to be administrated with a vaporiser by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM.
This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot.
Dr Axel Gille, president of Aurora Europe, commented: “Aurora’s participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatisation of medical cannabis in France.”
He added: “Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot programme could lead to one of the largest regulated markets for medical cannabis in Europe.”
The post First medical cannabis flower available for patients in France appeared first on Cannabis Health News.
